Navigation Links
Newly Patented Sterilization/Disinfection Method Reduces Risk of Microorganism Growth on Hard Surfaces
Date:7/21/2009

Bauer Energy Design® Inc. ("Bauer" or the "Company") is pleased to announce today that the U.S. Patent and Trademark Office has granted US Patent No. 7,547,413 to Bauer. This U.S. patent includes broad claims to novel methods and systems and their use in disinfecting or sterilizing a surface, an object or an environment with a special treated water steam.

Waterloo, Ontario, Canada (PRWEB) July 22, 2009 -- Bauer Energy Design® Inc. ("Bauer" or the "Company") is pleased to announce today that the U.S. Patent and Trademark Office has granted US Patent No. 7,547,413 to Bauer. This U.S. patent includes broad claims to novel methods and systems and their use in disinfecting or sterilizing a surface, an object or an environment with a special treated water steam.

The issuance of this patent provides broad patent protection for our water and steam vapour processing system and creates commercial opportunities for Bauer and his licensees in a broad commercial space. "Our system has applications in industry, including health care, livestock farms, meat processors, food manufacturers, food service facilities, schools and universities, as well as in domestic households," said Walter J. Bauer, President of the Company. Bauer's patent portfolio now includes one issued patent and two patent applications pending in multiple jurisdictions throughout the world.

Surface-mediated infectious disease transmission is a major concern in a variety of settings, including schools, hospitals, and food-processing facilities. Chemical disinfectants frequently used to reduce contamination pose significant risks to humans and the environment. Some microorganisms have natural resistance to chemical disinfectants which operate over a narrow range of pathogens. Additionally, the chemical formulations require long dwell or exposure times which are often overlo
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related medicine news :

1. First study examines newly-licensed RN work attitudes and intentions
2. Common abdominal pain may be due to a potentially treatable newly recognized inflammatory reaction
3. Higher death rates in kidney patients with newly recognized disease
4. Newly Published Study in Leading Medical Journal Further Confirms the Brava Systems Non-Surgical Breast Enhancement Effectiveness
5. Natural Nutrition Expands Revenue Capabilities with Newly Installed State of the Art Nutrition Bar Line
6. Corrected & Replaced - Natural Nutrition Expands Revenue Capabilities with Newly Installed State of the Art Nutrition Bar Line
7. Hidden Costs Plague Owners Occupying Newly Constructed Buildings; New Program Can Help Avoid Major Issues
8. Striking shift seen among newly HIV-infected men regarding partners
9. Newly HIV-Infected Gay Men Select Other Infected Partners
10. Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
11. New therapeutic options for newly diagnosed multiple myeloma patients
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 2Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 3Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 4ARKRAY, Inc. Receives FDA 510k Clearance on the Assure(R) Platinum Auto-Code Blood Glucose Monitoring System 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Service Corporation International Announces Schedule For Its Second Quarter 2009 Earnings Release and Conference Call 52397 1Service Corporation International Announces Schedule For Its Second Quarter 2009 Earnings Release and Conference Call 52397 2Biomodels Expands Efforts in Cancer Supportive Care Pulmonary Fibrosis 3B Preclinical Research Organization Names Dr Stephen T Sonis as Partner 13146 1Biomodels Expands Efforts in Cancer Supportive Care Pulmonary Fibrosis 3B Preclinical Research Organization Names Dr Stephen T Sonis as Partner 13146 2Is somatic hypersensitivity a predictor of irritable bowel syndrome 3F 52394 1Is somatic hypersensitivity a predictor of irritable bowel syndrome 3F 52394 2